Oral Oncology
Volume 37, Issue 7 , Pages 593-598, October 2001

Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer

  • T.T Sreelekha

      Affiliations

    • Department of Laboratory Medicine, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala State, India
  • ,
  • K Ramadas

      Affiliations

    • Department of Radiation Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala State, India
  • ,
  • M Pandey

      Affiliations

    • Department of Surgical Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala State, India
  • ,
  • G Thomas

      Affiliations

    • Department of Community Oncology, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala State, India
  • ,
  • K.R Nalinakumari

      Affiliations

    • Department of Dental Care, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala State, India
  • ,
  • M.R Pillai

      Affiliations

    • Department of Laboratory Medicine, Regional Cancer Centre, Thiruvananthapuram 695011, Kerala State, India
    • Corresponding Author InformationCorresponding author. Tel./fax: +91-471-447454

Received 24 November 2000; accepted 8 January 2001.

Abstract 

Oral cancer ranks first among all cancers in males and is the third most common among females in India. Tobacco-derived carcinogens are involved in the development of oral cancer. Environment–gene interaction in oral carcinogenesis is well demonstrated by phase I and II enzymes that are involved in the metabolism of carcinogens. This study looked at the significance of genetic polymorphisms in CYP1A1, GSTM1 and GSTT1 genes in patients with oral cancer. The study included 98 oral cancer patients and 60 age and sex matched healthy controls. Genotypes of CYP1A1, GSTM1 and GSTT1 were determined by PCR-RFLP. GSTM1 null deletion was observed in 49% of oral cancer cases and 33% of control subjects. For GSTT1, 18% of carcinomas and 8% of controls had the null genotype. In the case of CYP1A1 m2 allele, 51% of oral cancers and 17% of normal controls, respectively, had one or both alleles with the isoleucine→valine substitution. Digestion of the PCR products with enzyme Nco1 revealed polymorphism for CYP1A1 m2 with bands at 263 bp. There was no association between genotypes with tumor size, stage, grade, and age. Since null genotype individuals may possibly be poor detoxifiers with reduced ability to neutralise the reactive carcinogenic intermediates, they may be a high risk category. The frequency distribution of CYP1A1 m2 (Ile/val) genotypes among oral cancer patients was significantly different that from normal controls. The risk of CYP1A1 can be supported by the functional difference between presence of valine and isoleucine; valine type has higher catalytic and mutagenic activity towards benzo[a] pyrene than the isoleucine type. In conclusion, our results suggest that polymorphism in CYP1A1 m2 gene and/or GSTM1 and GSTT1 null genotype may confer an increased risk for oral cancer.

Keywords:  CYP1A1, GSTM1, GSTT1, Polymorphism, Susceptibility, Oral cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1368-8375(01)00028-8

Oral Oncology
Volume 37, Issue 7 , Pages 593-598, October 2001